XIFAXAN has excellent insurance coverage for patients with overt HE1

The resources below can help you find coverage for some of your adult patients.

Look up coverage for XIFAXAN in your area, make PAs simpler, learn how to avoid denials, and locate a Low-income Subsidy for appropriate patients for XIFAXAN. When needed, we have an example of a Letter of Medical Necessity and a Tier Exemption Request as well.

 

Let’s get started. What do you need to know?
Look up coverage
Prior Authorizations
Low-income Subsidy

Get XIFAXAN coverage by plan in your area

The XIFAXAN Coverage Lookup Tool can help you determine how a patient's prescription drug insurance covers XIFAXAN in your ZIP code.*

 
Find helpful information if your patient’s plan requires a PA

Simplifying the PA process for XIFAXAN

Being proactive with PAs leads to higher approval rates.1 View the brochure below to see simple directions for submitting a PA for XIFAXAN when needed. And learn how to avoid common reasons for a denial by expanding the chart.

View PA Considerations Brochure

Reason for denial Considerations for avoiding denial
PA not completed Double-check PA, fill in missing information, and resubmit
Dosing does not match Indication Double-check dosing
  • For IBS-D: XIFAXAN 550 mg, three times a day/14 days, 42 tablets2
  • For HE: XIFAXAN 550 mg, twice daily, 60 tablets2; if coverage allows refills, write for 180 tablets
Invalid diagnosis code Double-check ICD-10 code and resubmit*
  • K58.0 Irritable bowel syndrome with diarhea3
  • K72.9 Hepatic failure, unspecified3
Did not try & fail formulary alternative Include information on why XIFAXAN is necessary and how you expect it to help the patient
Product is a plan exclusion Double-check coverage; Medicare excludes certain kinds of drugs, but XIFAXAN is not in those categories
Medication not covered You can ask insurance plan to reevaluate; XIFAXAN is covered for 99% of commercially insured patients and 96% of Medicare patients1†

*The ICD-10 Codes and all other patient access related information are provided for informational purposes only. It is the treating physician’s responsibility to determine the proper diagnosis, treatment and applicable ICD-10 Code.

†Salix Pharmaceuticals does not guarantee coverage or reimbursement for the product.

Expedite your PAs for XIFAXAN with CoverMyMeds

In 2018, PAs had a 91% approval rate for XIFAXAN for HE when submitted through CoverMyMeds.1 To start a PA for XIFAXAN, you can go to covermymeds.com or call 1-866-452-5017.

Letter of Medical Necessity†

For both commercially and government insured patients, your practice may need to file an appeal if a patient is denied coverage for XIFAXAN. Please fill out and submit a Letter of Medical Necessity on behalf of your patient who has been prescribed XIFAXAN.

View Letter of Medical Necessity example

Low-income Subsidy Program

Your eligible patients may be entitled to “Extra Help” through the Low-income Subsidy program.

LIS recipients are entitled to branded prescription drugs at an affordable cost—no more than $8.95/prescription—which is a Medicare Part D benefit.4

Your patient may already be enrolled, however, if they aren’t they can visit here to determine eligibility and apply for benefits.

View Low-income subsidy brochure

View a Tier Exemption request example

of commercially insured patients have coverage for XIFAXAN1*‡

Over half of these patients have access to XIFAXAN without any restrictions.

 

of Medicare patients have coverage for XIFAXAN1*‡

 
INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
  • There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
  • Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
  • In clinical studies, the most common adverse reactions for XIFAXAN were:
    • –HE (≥10%): Peripheral edema (15%), nausea (14%), dizziness (13%), fatigue (12%), and ascites (11%)
    • –IBS-D (≥2%): Nausea (3%), ALT increased (2%)
  • INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
  • XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.

SEE MORE
INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.